Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SMRP



This biomarker is also known as:
  • MSLN,
  • Soluble Mesothelin Related Peptide,

View in BioMuta


Soluble mesothelin-related protein (SMRP) is related to the mesothelin family of molecules. It is overexpressed in ovarian cancer, malignant pleural mesothelioma (MPM), and certain other cancers. One hypothesis for the origin of SMRP is that this mesothelin-like molecule was released from tumor cells into culture supernatants, sera, and malignant effusions from certain tumors. Another hypothesis is that SMRP is actually a proteolytically cleaved fragment of membrane-bound mesothelin. Currently SMRP is considered to be an isoform of mesothelin (MSLN). UniprotKB/SwissProt lists isoform 3 of human mesothelin (identifier Q13421-2) as SMRP.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Differentially expressed mesothelial protein. May comprise a biomarker panel with SPP1 (osteopontin). SMRP can be assayed using MESOMARK, a 2-step immunoenzymatic assay in an ELISA format with a 6-point calibration curve. The MESOMARK assay may be useful for the detection and management of mesothelioma.

Performance Comment

SMRP is a promising biomarker for malignant pleural mesothelioma (MPM) in both serum and pleural effusion fluid.



Phase: Two
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.